Health and Human Services Secretary Robert F. Kennedy Jr. has renewed a simple but pointed argument against irreversible medical interventions for minors experiencing gender dysphoria, comparing the decision to give children puberty blockers and cross sex hormones to other choices society has long decided kids are not mature enough to make on their own.
“Minors cannot drive, vote, join the army, get a tattoo, smoke, or drink, because we know that children do not fully understand the consequences of decisions with lifelong ramifications,” Kennedy wrote, laying out the logic that has become a central pillar of his position on youth gender medicine.
It is hard to argue with the basic premise. American law is built around the recognition that children’s brains are still developing and that they lack the judgment to weigh long-term consequences the way adults do. That is precisely why a sixteen-year-old cannot sign a contract, buy a beer, or enlist in the military without parental consent. Kennedy’s argument simply asks why that same logic should not apply when the decision in question involves permanent changes to a child’s body and reproductive future.
Kennedy has been consistent on this point for some time, saying he has grown increasingly troubled by the practice of prescribing puberty blockers to minors as he has learned more about the issue. He has referred to the drugs bluntly as “castration drugs” and described some surgical interventions as “surgical mutilation,” language that has drawn sharp criticism from activist groups but that reflects a growing unease among parents across the political spectrum about how quickly pediatric medicine embraced these treatments over the past decade.
As HHS Secretary, Kennedy has moved beyond rhetoric into policy. His department released an updated report earlier this year that is sharply critical of gender affirming care for minors, building on an earlier May report that found the harms associated with these interventions, including puberty blockers, cross sex hormones, and surgical procedures, to be significant, long term, and too often inadequately tracked by the medical establishment that has championed them.
In a statement accompanying the report, Kennedy said such treatments have “inflicted lasting physical and psychological damage on vulnerable young people.” That is a serious claim, and it lines up with a growing body of concern out of several European countries that have themselves pulled back sharply on youth gender medicine after their own government reviews.
Sweden, Finland, and the United Kingdom have all significantly restricted access to puberty blockers and hormone therapy for minors in recent years after their own health authorities concluded that the evidence supporting these interventions was weaker than initially presented, and that psychotherapy and watchful waiting should be the default approach for most young people experiencing gender dysphoria. The United Kingdom’s landmark Cass Review, an independent look at the evidence commissioned by the National Health Service, found that the research underpinning pediatric gender medicine was of remarkably low quality given how widely the treatments had already been adopted.
That international shift matters context wise. Kennedy is not some lone outlier pushing a fringe position. He is aligning American policy with a broader reassessment that has already taken place among some of the very countries that pioneered gender affirming care for minors in the first place. It is worth asking why it took years longer for that same scrutiny to reach American medical institutions.
Predictably, major American medical organizations have pushed back hard against Kennedy’s position. The American Medical Association and other groups continue to support psychological and medical treatment for transgender identifying minors, and critics have accused Kennedy of ignoring scientific consensus in favor of ideology. Yale pediatrics professor Meredithe McNamara has been among the most vocal critics, warning that Kennedy’s influence could spread what she calls disinformation that lands hardest on kids who need care.
But “consensus” is doing a lot of work in that argument, and it is worth remembering that American medical consensus has been wrong before, sometimes for years, before catching up to evidence that was already clear elsewhere. The same organizations now defending youth gender medicine were, until very recently, largely dismissive of the very concerns that led European health systems to pull back. Deferring automatically to institutional consensus is not the same thing as being right.
